Evolent Health price target raised to $30 from $20 at SunTrust
SunTrust analyst Sandy Draper raised his price target for Evolent Health to $30 and reiterated a Buy rating on the shares after the company announced three Florida Medicaid deal wins, bringing the total to four partnerships that will serve five Florida Medicaid regions. In a research note to investors, Draper said he is not changing his estimates after the deals, but they do provide incremental visibility into 2019 estimates, and thinks the size and scope of the deals further illustrates the market need for Evolent's provider-sponsored health plan services and improving pipeline conditions